UNSPSC 51143500: Combination antiparkinson agents

This classification denotes combination drugs used in the treatment of a progressive, degenerative neurologic disease characterized by a tremor that is maximal at rest, retropulsion, rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression, a disorder called Parkinson Disease, hence the term ANTIPARKINSON AGENTS. Typical combination Antiparkinson agent constituents are carbidopa and levodopa.

UNSPSC 51143500 Combination antiparkinson agents is a Class code that does not align with the state and local procurement activity recorded under it. The single recent opportunity in the dataset — Seminole County, Florida's IFB for naloxone and drug deactivation systems — falls outside the code's nominal pharmaceutical scope; naloxone is an opioid antagonist used in overdose reversal and community harm reduction, not an antiparkinson agent. The mismatch suggests either a data-entry error in the source system or a jurisdiction's misclassification of the solicitation.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The response deadline was July 26, 2023, with electronic submission required through the county's e-Procurement Portal. Vendors must include all shipping and delivery costs in their bids, provide unit pricing for each line item, maintain workers' compensation and commercial general liability coverage, and comply with drug-free workplace certification and E-Verify requirements. The contract term was two years with a one-year renewal option and included a three-month probationary termination clause. The procurement notes potential FEMA funding and associated federal compliance obligations. No explicit set-aside designations for disadvantaged enterprises were specified. The code shows limited relevant recent activity for firms pursuing state and local pharmaceutical supply contracts under its stated classification.